Cardiac resynchronisation therapy study results
| Study | Randomly selected patients | Enrolment | Inclusion criteria | End points | Results |
|---|---|---|---|---|---|
| Path-CHF, pacing therapies for congestive heart failure; MUSTIC, multisite stimulation in cardiomyopathy; MIRACLE, multicentre InSync randomized clinical evaluation; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; Qol, quality of life; VO2, oxygen consumption. | |||||
| Path-CHF I 8,9,10 | 42 | 1996-99 | NYHA III-IV, QRS >120 ms, PR >150ms, sinus rhythm >55 bpm | Peak VO2, NYHA class, 6 min walk, QoL, hospitalisation | Improved peak VO2, 6 min walk distance, NYHA class, QoL LV volumes |
| InSync11 | 103 | 1966-67 | NYHA III–IV, LVEF <35%, LVEDD >60 mm, QRS >150 ms | NYHA class, QoL, 6 min walk, QRS width | Improved 6 min walk, NYHA, and QoL |
| MUSTIC-SR12 | 131 | 1998-99 | NYHA III-IV, LVEF <35%, LVEDD >60 mm, QRS <150 ms, 6 min walk <450 m | 6 min walk, QoL, hospitalisation, peak VO2 | Improved 6 min walk, QoL, reduced hospitalisation |
| MIRACLE13 | 452 | 1998-2000 | NYHA III-IV, LVEF <35%, LVEDD >55 mm, QRS >130 ms, no pacemaker | NYHA class, QoL, 6 min walk, peak VO2, hospitalisation, neurohormone values, echo indices, mortality | Improved NYHA class, 6 min walk, QoL, LVEF, LV volumes and MR, hospitalisation |